Bosch-Barrera, J.; Roqué, A.; Teixidor, E.; Carmona-Garcia, M.C.; Arbusà, A.; Brunet, J.; Martin-Castillo, B.; Cuyàs, E.; Verdura, S.; Menendez, J.A.
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals 2022, 15, 19.
https://doi.org/10.3390/ph15010019
AMA Style
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA.
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals. 2022; 15(1):19.
https://doi.org/10.3390/ph15010019
Chicago/Turabian Style
Bosch-Barrera, Joaquim, Ariadna Roqué, Eduard Teixidor, Maria Carmen Carmona-Garcia, Aina Arbusà, Joan Brunet, Begoña Martin-Castillo, Elisabet Cuyàs, Sara Verdura, and Javier A. Menendez.
2022. "Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin" Pharmaceuticals 15, no. 1: 19.
https://doi.org/10.3390/ph15010019
APA Style
Bosch-Barrera, J., Roqué, A., Teixidor, E., Carmona-Garcia, M. C., Arbusà, A., Brunet, J., Martin-Castillo, B., Cuyàs, E., Verdura, S., & Menendez, J. A.
(2022). Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 15(1), 19.
https://doi.org/10.3390/ph15010019
